Results of the real-time PCR showed that inhibition of PODXL-downregulated TAZ downstream targets including AXL, CTGF, CYR61, Survivin, and CyclinD1 (Figure 2B), confirming the association between PODXL and the TAZ signature in colon cancer patients. The gene discussed is BIRC5; the disease is malignant colon neoplasm.